Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lissoni

Showing results (71-80 of 287) with videos related to

Pageof 29
Sort By:
The International Journal of Biological Markers|November 24, 1999
Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2P Lissoni, S Bolis, M Mandalà, et al.
The International Journal of Biological Markers|July 7, 2000
Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancerA Bonfanti, P Lissoni, R Bucovec, et al.
Tumori|April 30, 1989
Malignant testicular germ cell tumor in father and son: a case reportS Crispino, G Lombardi, G Bratina, et al.
Recenti Progressi in Medicina|August 6, 1998
[Pharmacokinetics of melatonin]P Lissoni, F Rovelli, G Fumagalli, et al.
The International Journal of Biological Markers|July 1, 1997
Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observationsP Lissoni, F Rovelli, L Fumagalli, et al.
Tumori|December 31, 1990
Evaluation of the cardiovascular toxicity related to cancer immunotherapy with interleukin-2 by monitoring atrial natriuretic peptide secretion: a case reportP Lissoni, S Barni, G Cattaneo, et al.
Oncology|July 1, 1996
Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patientsF Brivio, P Lissoni, G Alderi, et al.
Tumori|January 1, 1995
Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapyF Paolorossi, S Villa, S Barni, et al.
Tumori|June 30, 1994
Ondansetron does not stimulate prolactin release in breast cancer patientsP Lissoni, M Cazzaniga, F Rovelli, et al.
Neuro Endocrinology Letters|May 4, 2001
Anti-angiogenic activity of melatonin in advanced cancer patientsP Lissoni, F Rovelli, F Malugani, et al.
Pageof 29

Showing results (71-80 of 287) with videos related to

Sort By:
Pageof 29
The International Journal of Biological Markers|November 24, 1999
Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2P Lissoni, S Bolis, M Mandalà, et al.
The International Journal of Biological Markers|July 7, 2000
Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancerA Bonfanti, P Lissoni, R Bucovec, et al.
Tumori|April 30, 1989
Malignant testicular germ cell tumor in father and son: a case reportS Crispino, G Lombardi, G Bratina, et al.
Recenti Progressi in Medicina|August 6, 1998
[Pharmacokinetics of melatonin]P Lissoni, F Rovelli, G Fumagalli, et al.
The International Journal of Biological Markers|July 1, 1997
Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observationsP Lissoni, F Rovelli, L Fumagalli, et al.
Tumori|December 31, 1990
Evaluation of the cardiovascular toxicity related to cancer immunotherapy with interleukin-2 by monitoring atrial natriuretic peptide secretion: a case reportP Lissoni, S Barni, G Cattaneo, et al.
Oncology|July 1, 1996
Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patientsF Brivio, P Lissoni, G Alderi, et al.
Tumori|January 1, 1995
Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapyF Paolorossi, S Villa, S Barni, et al.
Tumori|June 30, 1994
Ondansetron does not stimulate prolactin release in breast cancer patientsP Lissoni, M Cazzaniga, F Rovelli, et al.
Neuro Endocrinology Letters|May 4, 2001
Anti-angiogenic activity of melatonin in advanced cancer patientsP Lissoni, F Rovelli, F Malugani, et al.
Pageof 29